Heptares Grants Shire An Exclusive Worldwide Licence To Develop And Commercialise Novel Drug Candidate For CNS Disorders
Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. We have established R&D collaborations with Shire, Takeda, AstraZeneca, MedImmune and Novartis Option Fund, and have raised $40M in venture financing from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. Heptares is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that modulate historically undruggable or challenging GPCRs. Our integrated discovery platform includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time. Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, autism, anxiety & depression, chronic insomnia, addiction and diabetes. For more information, please visit http://www.heptares.com.
- Langmead, C. et al. (2012) J. Med. Chem. DOI: 10.1021/jm201455y. Published online: January 17, 2012
- Congreve, M. et al. (2012) J. Med. Chem. DOI: 10.1021/jm201376w. Published online: January 5, 2012
- Zhukov, A. et al. (2012) J. Med. Chem., 2011, 54 (13), pp 4312-4323
Contact Information Citigate DeweRogerson (for Heptares) Mark Swallow, Chris Gardner +1 857-222-4586 email@example.com +44 (0)20-7282-2948 firstname.lastname@example.org Heptares Therapeutics Ltd Malcolm Weir, Chief Executive Officer (UK) +44 (0)1707-358-629 email@example.com Dan Grau, President ( USA) +1-857-222-4586 firstname.lastname@example.org
SOURCE Heptares Therapeutics
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV